A team from MD Anderson directed by Tezvani et al. recently published a very encouraging phase I/II clinical trial testing the injection of CAR-NK-CD19 cells derived from fresh UCB in 11 patients suffering from relapsed refractory B-cell malignancies raging from non-Hodgkin lymphomas to chronic lymphocytic leukemia (ClinicalTrials.gov, NCT03056339). This evidence concerns the gene CD19 and non-Hodgkin lymphoma.